Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?
Metastatic melanoma has been associated with a poor prognosis, with overall survival rates at 5 years of 10%. Until 2011, the only treatments available for metastatic melanoma were chemotherapy and immunotherapy with interleukin-2. The more in-depth knowledge about the molecular biology of melanoma...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Kitap |
| Baskı/Yayın Bilgisi: |
Sociedade Portuguesa de Dermatologia e Venereologia,
2021-06-01T00:00:00Z.
|
| Konular: | |
| Online Erişim: | Connect to this object online. |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
| Özet: | Metastatic melanoma has been associated with a poor prognosis, with overall survival rates at 5 years of 10%. Until 2011, the only treatments available for metastatic melanoma were chemotherapy and immunotherapy with interleukin-2. The more in-depth knowledge about the molecular biology of melanoma and the identification of BRAF mutations, which are the most frequently found, allowed us to find new therapeutic targets that came to modify the prognosis of these patients. Currently, the treatments available for metastatic melanoma with BRAF mutation are immunotherapy with immunological checkpoint inhibitors (anti-PD-1 to anti-CTLA-4) and targeted therapy with BRAF inhibitors and MEK inhibitors. However, the first-line therapy to be instituted in these patients remains unknown. |
|---|---|
| Diğer Bilgileri: | 10.29021/spdv.79.2.1342 2182-2395 2182-2409 |